Nxera Pharma to Receive $8.6M Milestone Payment from Centessa for OX2R Development
Tokyo, Japan and Cambridge, UK, September 3, 2026 Nxera Pharma announced that Centessa Pharmaceuticals, a wholly owned subsidiary of...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Tokyo, Japan and Cambridge, UK, September 3, 2026 Nxera Pharma announced that Centessa Pharmaceuticals, a wholly owned subsidiary of...
OSAKA, Japan & CAMBRIDGE, Massachusetts, Aug 24, 2026 Takeda Pharmaceutical Company Limited announced that Japan’s Ministry of Health, Labour...
